Publications
BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction.. Science. 10.1126/science.adq2004
(2025) Biophysical and structural analysis of KRAS switch-II pocket inhibitors reveals allele-specific binding constraints. J Biol Chem. 10.1016/j.jbc.2025.110331
(2025) Discovery of BBO-8520, a first-in-class direct and covalent dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C. Cancer Discov. 10.1158/2159-8290.CD-24-0840
(2024)